Use of GLP-1 mimetic in type 2 diabetes mellitus: is it the end of fragility fractures?
Endocrine
.
2015 Feb;48(1):1-2.
doi: 10.1007/s12020-014-0461-1.
Epub 2014 Oct 28.
Author
Guillaume Mabilleau
1
Affiliation
1
GEROM Groupe Etudes Remodelage Osseux et bioMatériaux - UPRES EA 4658 LHEA, IRIS-IBS Institut de Biologie en Santé, CHU d'Angers, LUNAM Université, 4 rue Larrey, 49933, Angers Cedex 09, France, guillaume.mabilleau@univ-angers.fr.
PMID:
25348148
DOI:
10.1007/s12020-014-0461-1
No abstract available
Publication types
Editorial
Comment
MeSH terms
Fractures, Bone / epidemiology*
Fractures, Bone / etiology*
Humans
Hypoglycemic Agents / adverse effects*
Receptors, Glucagon / agonists*
Substances
Hypoglycemic Agents
Receptors, Glucagon